Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.93
- Piotroski Score 2.00
- Grade Neutral
- Symbol (PROK)
- Company ProKidney Corp.
- Price $1.86
- Changes Percentage (-9.07%)
- Change -$0.19
- Day Low $1.80
- Day High $2.03
- Year High $4.85
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/09/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $6.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.57
- Trailing P/E Ratio -5.6
- Forward P/E Ratio -5.6
- P/E Growth -5.6
- Net Income $-35,468,000
